Autoimmune therapies found wanting in type 1 diabetes
This article was originally published in Scrip
Executive Summary
Autoimmune treatments in type 1 diabetes hold forth the promise of preserving the body’s own insulin production. However, three late-stage candidates – teplizumab, otelixizumab, and Diamyd – have failed to show that they can prevent beta-cell destruction in type 1 patients.